Abstract
Rationale: Amisulpride (Sanofi) is atypical antipsychotic against both positive and negative symptoms of schizophrenia . Efficacy is observed against negative symptoms in a low dose range of ( 50-300 mg / day ) while in positive symptoms is observed in a high dose range ( 800-1200 mg / day ) Boyer et al ,( 1994 ). It is a selective and potent antagonist at dopamine D2 and D3 receptors. Also it appears to have a useful potential for treatment of depression Boyer et al ,(1999). Objectives: The current study investigated that amisulpride has antidepressant properties over a range of doses in two procedures namely the Forced Swim Test (FST) Porso et al,(1978) and immune-histopathology of Ki67. Also the effect of high versus low dose of amisulpride on hippocampal neurogenesis in male Wistar Han albino rats. Results: There is an increase of immobility time in seconds in CSS group compared with Control group with Mean ± SD (67.00±8.623 and 3.333±1.670 respectively) with P treatment with oral Amisulpride 5 ,10 mg/kg/day result in insignificant increase in Ki-67 immunostained cells in SVZ, with the maximum statistically increase with 20 mg/kg/day, with means (15.78,13.38 and 28.00 respectively )compared with CSS (Mean 8.000 ) with P values of 0.5108 ,0.8187and 0.0009 respectively and F (4,40)=6.628.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
